ARTICLE | Company News
Egenix, Harvard deal
February 4, 2008 8:00 AM UTC
The university granted Egenix exclusive rights to cancer compounds and prognostic markers for various cancers. The small molecule inhibitors of the eukaryotic translation initiation factor 4F (eIF4F)...